ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 21, 2019
31 Mai 2019 - 6:00PM
LYON, France, May 31, 2019 (GLOBE
NEWSWIRE) -- ERYTECH
Pharma (Euronext Paris: ERYP -
Nasdaq: ERYP), a clinical-stage
biopharmaceutical company developing innovative therapies by
encapsulating drug substances inside red blood
cells, today announced
that the availability of the
documents for its Annual General Meeting to be held on June 21,
2019.
ERYTECH's shareholders are hereby
informed of the Annual General Meeting which will take place on
June 21, 2019 at 09:30am CET at the Centre Edouard VII, 23 Rue
Édouard VII, 75009 Paris (FRANCE).
The meeting and convening notice
(l'avis de réunion valant convocation)
containing the detailed agenda, draft resolutions as well as
instructions to participate and vote for the Annual General Meeting
was published in the French official legal announcement publication
"Bulletin des Annonces Légales Obligatoires"
(BALO) N°59 of May 17, 2019 and in "l'ESSOR" n# ES173392 on May 31,
2019.
Pursuant to applicable French laws
and regulations, the preparatory documents and information for the
Annual General Meeting are available and posted on the Company's
website www.erytech.com, under the section « Investors /
Shareholders Meeting / General Meeting 2019 ».
About
ERYTECH: www.erytech.com
ERYTECH is a clinical-stage
biopharmaceutical company developing innovative red blood
cell-based therapeutics for severe forms of cancer and orphan
diseases. Leveraging its proprietary ERYCAPS platform, which uses a
novel technology to encapsulate drug substances inside red blood
cells, ERYTECH is developing a pipeline of product candidates for
patients with high unmet medical needs.
ERYTECH's primary focus is on the
development of product candidates that target the altered
metabolism of cancer cells by depriving them of amino acids
necessary for their growth and survival. The Company's lead product
candidate, eryaspase, which consists of L-asparaginase encapsulated
inside donor-derived red blood cells, targets the cancer cell's
altered asparagine and glutamine metabolism. Eryaspase is in Phase
3 clinical development for the treatment of second-line pancreatic
cancer and in Phase 2 for the treatment of triple-negative breast
cancer. ERYTECH is also developing erymethionase, which consists of
methionine-gamma-lyase encapsulated in red blood cells to target
methionine-dependent cancers.
ERYTECH produces product
candidates at its GMP-approved manufacturing site in Lyon,
France, and at the American Red Cross in Philadelphia, USA. A
large-scale GMP manufacturing facility has recently completed
construction in Princeton, New Jersey, USA.
ERYTECH is
listed on the Nasdaq Global Select Market in the United
States (ticker: ERYP) and on the Euronext regulated
market in Paris (ISIN code: FR0011471135, ticker: ERYP).
ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio,
CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and
Next Biotech indexes.
CONTACTS
ERYTECH
Eric Soyer
CFO & COO
|
NewCap
Mathilde Bohin / Louis-Victor
Delouvrier
Investor relations
Nicolas Merigeau
Media relations
|
+33 4 78
74 44 38
investors@erytech.com |
+33 1 44
71 98 52
erytech@newcap.eu |
PDF
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Erytech Pharma S.A. via Globenewswire